Is NVS or OCS more undervalued in 2026?

CirclFi compares Novartis AG (NVS) and Oculis Holding AG (OCS) using 13 institutional-grade valuation models. NVS has a Quality of Company score of 2.4/10 while OCS scores 3.7/10.

Which is a better buy — NVS or OCS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NVS and OCS valuations compare?

NVS at $150.17 and OCS at $22.70 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NVS vs OCS Valuation Comparison 2026 — Intrinsic Value Analysis

NVS

Pharmaceutical Preparations

Novartis AG

Quality

2.4

out of 10

Value Trap

—

Price

$150.17

Last close

Models

13/13

Active

OCS

Pharmaceutical Preparations

Oculis Holding AG

Quality

3.7

out of 10

Value Trap

SAFE

Price

$22.70

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	NVS Fair Value	NVS Upside	OCS Fair Value	OCS Upside
Bayesian DCF	Intrinsic	$37.90	-74.8%	$8.44	-62.8%
Earnings Power Value	Intrinsic	$96.94	-34.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$12.09	-92.0%	$2.25	-90.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NVS vs OCS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NVS vs OCS — Which Stock Is More Undervalued?

OCS scores higher with a 3.7/10 quality rating vs NVS's 2.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Novartis AG (NVS) and Oculis Holding AG (OCS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NVS currently trades at $150.17 with a QOC of 2.4/10, while OCS trades at $22.70 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).